A citation-based method for searching scientific literature

M Augustin, M Valencia López, K Reich. J Eur Acad Dermatol Venereol 2021
Times Cited: 2







List of co-cited articles
4 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Rapid Response of Biologic Treatments of Moderate-to-Severe Plaque Psoriasis: A Comprehensive Investigation Using Bayesian and Frequentist Network Meta-analyses.
Richard B Warren, Kyoungah See, Russel Burge, Ying Zhang, Alan Brnabic, Gaia Gallo, Alyssa Garrelts, Alexander Egeberg. Dermatol Ther (Heidelb) 2020
21
100

Matching-adjusted indirect comparison of efficacy in patients with moderate-to-severe plaque psoriasis treated with ixekizumab vs. secukinumab.
R B Warren, A Brnabic, D Saure, R G Langley, K See, J J Wu, A Schacht, L Mallbris, A Nast. Br J Dermatol 2018
33
100

The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis.
Laura Sawyer, Iain Fotheringham, Emily Wright, Najeeda Yasmeen, Carl Gibbons, Anders Holmen Møller. J Dermatolog Treat 2018
24
100

Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response.
Laura M Sawyer, Kinga Malottki, Celia Sabry-Grant, Najeeda Yasmeen, Emily Wright, Anne Sohrt, Emma Borg, Richard B Warren. PLoS One 2019
81
100

Users of biologics in clinical practice: would they be eligible for phase III clinical studies? Cohort Study in the French Psoriasis Registry PSOBIOTEQ.
M Masson Regnault, J Castañeda-Sanabria, M H T Diep Tran, M Beylot-Barry, H Bachelez, N Beneton, O Chosidow, A Dupuy, P Joly, D Jullien,[...]. J Eur Acad Dermatol Venereol 2020
27
50

Drug survival of ixekizumab, TNF inhibitors, and other IL-17 inhibitors in real-world patients with psoriasis: The Corrona Psoriasis Registry.
Benjamin Lockshin, Angel Cronin, Ryan W Harrison, Robert R McLean, Laura Anatale-Tardiff, Russel Burge, Baojin Zhu, William N Malatestinic, Bilal Atiya, Mwangi J Murage,[...]. Dermatol Ther 2021
10
50

Psoriasis therapy in real life: the need for registries.
Marcus Schmitt-Egenolf. Dermatology 2006
45
50

Sensitivity Analysis in Observational Research: Introducing the E-Value.
Tyler J VanderWeele, Peng Ding. Ann Intern Med 2017
50

Network meta-analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values ≤1, 2, 3 or 5 derived from a statistical conversion method.
U Mrowietz, R B Warren, C L Leonardi, D Saure, H Petto, S Hartz, M Dossenbach, K Reich. J Eur Acad Dermatol Venereol 2021
6
50

Real-world, long-term treatment patterns of commonly used biologics in Canadian patients with moderate-to-severe chronic plaque psoriasis.
Melinda J Gooderham, Charles Lynde, Irina Turchin, Miriam Avadisian, Melanie Labelle, Kim A Papp. J Dermatol 2022
4
50

Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities?
Daniel C Baumgart, Laurent Misery, Sue Naeyaert, Peter C Taylor. Front Pharmacol 2019
59
50

Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials.
Ignacio Garcia-Doval, Gregorio Carretero, Francisco Vanaclocha, Carlos Ferrandiz, Esteban Daudén, Jose-Luis Sánchez-Carazo, Mercé Alsina, Enrique Herrera-Ceballos, Francisco-José Gómez-García, Marta Ferrán,[...]. Arch Dermatol 2012
129
50

Characteristics and Medication Use of Psoriasis Patients Who May or May Not Qualify for Randomized Controlled Trials.
William Malatestinic, Beth Nordstrom, Jashin J Wu, Orin Goldblum, Kathleen Solotkin, Chen-Yen Lin, Kristin Kistler, Kathy Fraeman, Joseph Johnston, Lcdr Lesley Hawley,[...]. J Manag Care Spec Pharm 2017
15
50



Use of biologics for psoriasis in Central and Eastern European countries.
F Rencz, L Kemény, J Z Gajdácsi, W Owczarek, P Arenberger, G S Tiplica, A Stanimirović, M Niewada, G Petrova, L T Marinov,[...]. J Eur Acad Dermatol Venereol 2015
33
50

Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study.
Tiago Torres, Luis Puig, Ron Vender, Charles Lynde, Stefano Piaserico, Jose M Carrascosa, Paolo Gisondi, Esteban Daudén, Curdin Conrad, Pedro Mendes-Bastos,[...]. Am J Clin Dermatol 2021
26
50

Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Emilie Sbidian, Anna Chaimani, Ignacio Garcia-Doval, Liz Doney, Corinna Dressler, Camille Hua, Carolyn Hughes, Luigi Naldi, Sivem Afach, Laurence Le Cleach. Cochrane Database Syst Rev 2021
25
50

Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.
Yayoi Tada, Rei Watanabe, Hisashi Noma, Yasumasa Kanai, Takanobu Nomura, Kenji Kaneko. J Dermatol Sci 2020
15
50

Indirect comparisons of ixekizumab versus three interleukin-23 p19 inhibitors in patients with moderate-to-severe plaque psoriasis - efficacy findings up to week 12.
Alice B Gottlieb, Daniel Saure, Stefan Wilhelm, Martin Dossenbach, Christopher Schuster, Saxon D Smith, Yuval Ramot, Diamant Thaçi. J Dermatolog Treat 2022
5
50

Evaluating bias control strategies in observational studies using frequentist model averaging.
Anthony Zagar, Zbigniew Kadziola, Ilya Lipkovich, David Madigan, Doug Faries. J Biopharm Stat 2022
2
50

Psoriasis registries worldwide: systematic overview on registry publications.
L Eissing, S J Rustenbach, M Krensel, N Zander, C Spehr, M A Radtke, L Naldi, M Augustin. J Eur Acad Dermatol Venereol 2016
25
50

Reaching complete or near-complete resolution of psoriasis: benefit and risk considerations.
A Blauvelt, C E M Griffiths, M Lebwohl, U Mrowietz, L Puig, S Ball, L Zhang, E Edson-Heredia, M Warner, B Zhu,[...]. Br J Dermatol 2017
8
50


Patient-relevant treatment goals in psoriasis.
Christine Blome, Ramona Gosau, Marc A Radtke, Kristian Reich, Stephan J Rustenbach, Christina Spehr, Diamant Thaçi, Matthias Augustin. Arch Dermatol Res 2016
72
50

Anti-IL17 therapies for psoriasis.
Annika Silfvast-Kaiser, So Yeon Paek, Alan Menter. Expert Opin Biol Ther 2019
43
50

Biologic drug survival rates in the era of anti-interleukin-17 antibodies: a time-period-adjusted registry analysis.
T Graier, W Salmhofer, C Jonak, W Weger, C Kölli, B Gruber, P G Sator, K Prillinger, A Mlynek, M Schütz-Bergmayr,[...]. Br J Dermatol 2021
19
50

Comparative Efficacy and Relative Ranking of Biologics and Oral Therapies for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis.
April W Armstrong, Ahmed M Soliman, Keith A Betts, Yan Wang, Yawen Gao, Luis Puig, Matthias Augustin. Dermatol Ther (Heidelb) 2021
18
50

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.
Alan Menter, Bruce E Strober, Daniel H Kaplan, Dario Kivelevitch, Elizabeth Farley Prater, Benjamin Stoff, April W Armstrong, Cody Connor, Kelly M Cordoro, Dawn M R Davis,[...]. J Am Acad Dermatol 2019
303
50


Efficacy of several biological therapies for treating moderate to severe psoriasis: A network meta-analysis.
Wenjun Geng, Jianhua Zhao, Jixing Fu, Huamin Zhang, Shaohua Qiao. Exp Ther Med 2018
14
50

Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis.
April W Armstrong, Luis Puig, Avani Joshi, Martha Skup, David Williams, Junlong Li, Keith A Betts, Matthias Augustin. JAMA Dermatol 2020
83
50



Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis.
Richard B Warren, Melinda Gooderham, Russel Burge, Baojin Zhu, David Amato, Karen Huayu Liu, David Shrom, Jiaying Guo, Alan Brnabic, Andrew Blauvelt. J Am Acad Dermatol 2020
25
50

Network Meta-analysis of Treatments for Chronic Plaque Psoriasis in Canada.
Aditya K Gupta, Deanne Daigle, Danika C A Lyons. J Cutan Med Surg 2014
11
50


Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Emilie Sbidian, Anna Chaimani, Ignacio Garcia-Doval, Giao Do, Camille Hua, Canelle Mazaud, Catherine Droitcourt, Carolyn Hughes, John R Ingram, Luigi Naldi,[...]. Cochrane Database Syst Rev 2017
153
50

Importance of assessing and adjusting for cross-study heterogeneity in network meta-analysis: a case study of psoriasis.
Chris Cameron, Brian Hutton, Cheryl Druchok, Sean McElligott, Sandhya Nair, Agata Schubert, Aaron Situ, Abhishek Varu, Reggie Villacorta. J Comp Eff Res 2018
19
50

Is providing uncertainty intervals in treatment ranking helpful in a network meta-analysis?
Areti Angeliki Veroniki, Sharon E Straus, Gerta Rücker, Andrea C Tricco. J Clin Epidemiol 2018
38
50

Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis.
Zarif K Jabbar-Lopez, Zenas Z N Yiu, Victoria Ward, Lesley S Exton, M Firouz Mohd Mustapa, Eleanor Samarasekera, A David Burden, Ruth Murphy, Caroline M Owen, Richard Parslew,[...]. J Invest Dermatol 2017
91
50

Comparative efficacy and safety of thirteen biologic therapies for patients with moderate or severe psoriasis: A network meta-analysis.
Guomei Xu, Meng Xia, Chenjie Jiang, Ying Yu, Guomi Wang, Jiaojiao Yuan, Xingwu Duan. J Pharmacol Sci 2019
21
50



Approaches to interpreting and choosing the best treatments in network meta-analyses.
L Mbuagbaw, B Rochwerg, R Jaeschke, D Heels-Andsell, W Alhazzani, L Thabane, Gordon H Guyatt. Syst Rev 2017
205
50

AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both.
Beverley J Shea, Barnaby C Reeves, George Wells, Micere Thuku, Candyce Hamel, Julian Moran, David Moher, Peter Tugwell, Vivian Welch, Elizabeth Kristjansson,[...]. BMJ 2017
50

Biological treatments for moderate-to-severe psoriasis: indirect comparison.
M Galván-Banqueri, R Marín Gil, B Santos Ramos, F J Bautista Paloma. J Clin Pharm Ther 2013
32
50

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
Kenneth B Gordon, Bruce Strober, Mark Lebwohl, Matthias Augustin, Andrew Blauvelt, Yves Poulin, Kim A Papp, Howard Sofen, Lluís Puig, Peter Foley,[...]. Lancet 2018
290
50

Overview of methods for comparing the efficacies of drugs in the absence of head-to-head clinical trial data.
Hansoo Kim, Lyle Gurrin, Zanfina Ademi, Danny Liew. Br J Clin Pharmacol 2014
34
50

Comparison of Adalimumab and Etanercept for the Treatment of Moderate to Severe Psoriasis: An Indirect Comparison Using Individual Patient Data from Randomized Trials.
Kim A Papp, Min Yang, Murali Sundaram, John Jarvis, Keith A Betts, Yanjun Bao, James E Signorovitch. Value Health 2018
8
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.